NCT06540326

Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab

Clinical Study of Second-line Treatment of Patients With Advanced Colorectal Cancer With Irinotecan Liposome (II), Fluorouracil in Combination With Bevacizumab or Cetuximab

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Guidelines recommend FOLFIRI in combination with bevacizumab or cetuximab as a treatment option for advanced second-line colorectal cancer, and this study explores the efficacy and safety of a clinical study of liposomal irinotecan (II), fluorouracil, in combination with bevacizumab or cetuximab for the second-line treatment of patients with advanced colorectal cancer.

Detailed description

Guidelines recommend FOLFIRI in combination with bevacizumab or cetuximab as a treatment option for advanced second-line colorectal cancer. Liposomal irinotecan (II) compared with ordinary irinotecan can improve efficacy and safety. This study explores the efficacy and safety of a clinical study of liposomal irinotecan (II), fluorouracil, in combination with bevacizumab or cetuximab for the second-line treatment of patients with advanced colorectal cancer.

Conditions

• Colorectal Cancer Metastatic

Interventions

Type	Name	Description
DRUG	irinotecan liposome (II)	irinotecan liposome (II) is a powerful chemotherapeutic agents, in the combination with fluorouracil，and bevacizumab or cetuximab
DRUG	fluorouracil	fluorouracil is a powerful chemotherapeutic agents, in the combination with irinotecan liposome (II)，and bevacizumab or cetuximab
DRUG	cetuximab	cetuximab is a powerful targeted agents, in the combination with irinotecan liposome (II)，and fluorouracil
DRUG	bevacizumab	bevacizumab is a powerful targeted agents, in the combination with irinotecan liposome (II)，and fluorouracil
DRUG	Capecitabine	Capecitabine is a powerful chemotherapeutic agent, in the combination with bevacizumab or cetuximab

Timeline

• Start date: 2024-11-12
• Primary completion: 2026-04-15
• Completion: 2027-10-31
• First posted: 2024-08-06
• Last updated: 2025-12-22

Locations

1 site across 1 country: China